Scholar Rock Holding Corporation announced that it has commenced an underwritten public offering for $275M of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of its common stock. Scholar Rock intends to use the net proceeds from the offering to support commercialization of apitegromab, to advance its ongoing and future clinical programs, to further develop its technology platform to continue to advance its clinical and preclinical pipeline, and for working capital and other general corporate purposes. J.P. Morgan Securities, Jefferies and Piper Sandler & Co. are acting as joint book-running managers for the offering. BMO Capital Markets, Wedbush Securities and Raymond James & Associates are acting as co-managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock files automatic mixed securities shelf
- Scholar Rock price target raised to $37 from $27 at Wedbush
- RBC says Scholar Rock ‘win’ in SMA has favorable Biohaven implications
- Arcadium confirms Rio approach, Apollo funds to acquire Barnes: Morning Buzz
- Morning Movers: Duckhorn and Barnes rise after take-private deals